AI has the power to reshape drug discovery and patient care, but pharmaceutical companies are making a fundamental mistake in how they are approaching adoption. A vast majority of companies are attempting to treat their AI strategy as a standalone pivot instead of integrating it as a tool to accelerate the achievement of their strategic priorities. The critical question they all should be asking is, “How can AI advance our drug development strategy?” rather than, “What’s our AI strategy?”
When AI implementation operates independently from core business objectives, employees struggle to see its relevance and therefore struggle to adopt it in useful ways. Teams should first understand how these tools can help achieve your strategic priorities, then build use cases to enhance their daily work. The strategic understanding buoyed by practical application can accelerate adoption rates and measurable impact.
To help unlock AI’s true potential, pharma leaders can focus on four critical areas.
Focus on people, not just technology
Unlike previous technology rollouts, AI’s effectiveness depends entirely on how people use it. The same tool can produce dramatically different results depending on user engagement and know-how. This is particularly true for the generative AI and machine learning models now entering pharmaceutical workflows to redefine drug discovery.
Real value will emerge when users identify critical use cases for AI and identify the corresponding behavior shifts. To do this, leaders must start by explaining how AI safely supports the company’s mission and how it will help teams achieve their objectives. Without clear direction and safe experimentation guidelines, your AI adoption will likely remain at an operational level. Think summarizing research papers versus evaluating drug targets.
Another important consideration is addressing employees’ uncertainty about AI. For many, it remains an unfamiliar technology associated with ethical concerns and potential risks. Clearly linking AI adoption to broader strategic goals can help ease fears, particularly those amplified by media coverage of job losses. The aim should be to position AI as a tool that supports employees and enhances productivity, rather than one that threatens their livelihoods.
To reduce user resistance and lower fear barriers to engagement, employees need to understand specifically how AI can help them deliver treatments faster and improve patient outcomes while also solving those daily challenges creating capacity and efficiency.
Blend top-down vision with bottom-up innovation
To effectively integrate AI, pharmaceuticals companies need both executive alignment and grassroot experimentation. Leaders should connect AI initiatives to their organization’s strategy while empowering their teams to integrate the new tools into their work. This means gathering input from the front line such as lab scientists, trial managers, and regulatory specialists. People who actually use the tools in their daily work are in the best position to identify where AI can create opportunity and where human cognition remains essential.
Leaders can encourage experimentation by giving their employees the opportunity to experiment with use cases on AI design committees and evaluation groups. When you combine leadership’s strategic lens with frontline operational insights, maximizing the impact of technology becomes a lot easier. Engaging employees as partners in this transition will help create buy-in and allow the most impactful applications of AI to surface.
Survive into thrive
Even when aligned on a strategic vision, employees can feel overwhelmed to research and explore new ways of working all while still doing their day job. This is often due to fear of errors or that one is programming the technology that will eventually make their job obsolete. Such realities often stifle the innovative thinking required for AI adoption. Leaders can help their teams shift from survive mode to thrive mode by positioning AI as a tool that can expand the drug discovery capabilities and open new career prospects.
One effective technique for encouraging exploration is creating a sandbox environment where teams can experiment and collaborate with the AI applications without the pressure of making mistakes. For example, drug development teams can practice mapping chemical compounds before tackling urgent therapeutic challenges. These safe spaces will reduce fears while building AI capabilities and demonstrating the value of the technology, helping to assuage job displacement concerns.
Other acceleration techniques are removing approval layers for AI experimentation by forming dynamic cross-functional teams whose remit is AI exploration, engaging more people in AI problem-solving, and leveraging peer-to-peer engagement. These tactics build trust and energy around AI while lowering the fear barrier to usage through maintaining the safety, rigor, and compliance standards required in the pharmaceutical industry.
Learn from past mistakes
Treating AI as purely a technology challenge has the potential to produce results similar to the 1990s offshoring rush. Companies quickly moved manufacturing and research overseas to chase cost savings without fully considering impacts on quality control, intellectual property, or impact to workers and communities. This caused years of time and rework trying to reverse the damage caused by hasty decisions and chasing trends.
Pharma leaders can avoid repeating history by ensuring their AI use is strategically linked to their objectives, engaging employees as change partners, and building an adaptive culture that can efficiently and effectively welcome transformations.
Answering the right questions
Whether your focus is breakthrough therapies, clinical trial efficiency, or manufacturing improvements, AI can be a powerful enabler — but only with the right change approach. Leaders must recognize that this is a pivotal moment in the history of work, one based on technology, but which is fundamentally a people transformation. To be successful, leaders must engage employees to reimagine new ways of working all while measuring AI’s direct impact on strategic priorities. Connect AI clearly to strategic objectives, engage teams as partners in identifying applications, and foster cultures where experimentation thrives within appropriate boundaries.
The fundamental question isn’t “What’s our AI strategy?” It’s “How will AI help us achieve our mission?” Answer that first, and the path forward, along with the capabilities your teams need, will become clear.
